Wed. 22 May 2024, 4:14pm ET
Benzinga
Biotech, News, Events, General
- Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24
- Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24
- End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024